Drug Profile
Fexapotide - Nymox Pharmaceutical Corporation
Alternative Names: Fexapotide triflutate - Nymox Pharmaceutical Corporation; NX-1207; NYMOZARFEX; REC-0482Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nymox Pharmaceutical Corporation
- Developer Nymox Pharmaceutical Corporation; Recordati
- Class Antineoplastics; Proteins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Benign prostatic hyperplasia
- Phase II Prostate cancer
- No development reported Liver cancer
Most Recent Events
- 26 Oct 2023 United Kingdom Medicines & Healthcare products Regulatory Agency (UK-MHRA) accepts MAA for fexapotide for Benign prostatic hyperplasia for review
- 25 Sep 2023 Preregistration for Benign prostatic hyperplasia in England, Wales, Scotland, United Kingdom (Northern Ireland) (Intraprostatic)
- 25 Sep 2023 Nymox Pharmaceutical submits MAA to MHRA for Benign prostatic hyperplasia in England, Wales, Scotland and United Kingdom (Northern Ireland)